,19 Furthermore, osimertinib showed to prolong survival outcome irrespective of the presence of brain metastases and additionally prevented the occurrence of central nervous system (CNS) disease progression, which represented a common event in EGFR-mutated NSCLC.20 This evidence concerns the gene EGFR and non-small cell lung carcinoma.